Effect of Lactobacillus reuteri GMNL-263 treatment on renal fibrosis in diabetic rats

Lu, Ying‐Chen; Yin, Li-Te; Chang, Wen‐Cheng; Huang, Jau‐Shyang

doi:10.1016/j.jbiosc.2010.07.006

Cited by 43 publications

(33 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…41 When introduced in pigs, turkeys and rats, L. reuteri led to a significant weight gain and was isolated in higher concentrations from feces after probiotic administration. 42, 43, 44 The mechanism by which L. reuteri is able to support the healthy growth of these animals is not entirely understood. It is possible that L. reuteri simply serves to protect livestock against illness caused by Salmonella typhimurium and other pathogens.…”

Section: Discussionmentioning

confidence: 99%

RETRACTED ARTICLE: Obesity-associated gut microbiota is enriched in Lactobacillus reuteri and depleted in Bifidobacterium animalis and Methanobrevibacter smithii

Maraninchi²,

et al. 2011

View full text Add to dashboard Cite

Background:Obesity is associated with increased health risk and has been associated with alterations in bacterial gut microbiota, with mainly a reduction in Bacteroidetes, but few data exist at the genus and species level. It has been reported that the Lactobacillus and Bifidobacterium genus representatives may have a critical role in weight regulation as an anti-obesity effect in experimental models and humans, or as a growth-promoter effect in agriculture depending on the strains.Objectives and methods:To confirm reported gut alterations and test whether Lactobacillus or Bifidobacterium species found in the human gut are associated with obesity or lean status, we analyzed the stools of 68 obese and 47 controls targeting Firmicutes, Bacteroidetes, Methanobrevibacter smithii, Lactococcus lactis, Bifidobacterium animalis and seven species of Lactobacillus by quantitative PCR (qPCR) and culture on a Lactobacillus-selective medium.Findings:In qPCR, B. animalis (odds ratio (OR)=0.63; 95% confidence interval (CI) 0.39–1.01; P=0.056) and M. smithii (OR=0.76; 95% CI 0.59–0.97; P=0.03) were associated with normal weight whereas Lactobacillus reuteri (OR=1.79; 95% CI 1.03–3.10; P=0.04) was associated with obesity.Conclusion:The gut microbiota associated with human obesity is depleted in M. smithii. Some Bifidobacterium or Lactobacillus species were associated with normal weight (B. animalis) while others (L. reuteri) were associated with obesity. Therefore, gut microbiota composition at the species level is related to body weight and obesity, which might be of relevance for further studies and the management of obesity. These results must be considered cautiously because it is the first study to date that links specific species of Lactobacillus with obesity in humans.

show abstract

Section: Discussionmentioning

confidence: 99%

RETRACTED ARTICLE: Obesity-associated gut microbiota is enriched in Lactobacillus reuteri and depleted in Bifidobacterium animalis and Methanobrevibacter smithii

Maraninchi²,

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Their mechanisms are perhaps suggestive by dihydropyridine calcium channel blockers which are not as impressive as ACE (Angiotensin-Converting-Enzyme) inhibitors or angiotensin receptor blocker (ARB) in reducing albuminuria [8]. High glucose products abnormally high amounts of free radicals by autoxidation of glucose and protein glycation, and oxidative stress has been reported to be a causal agent of tubule interstitial fibrosis in patients with diabetic nephropathy (DN) [33]. In fact, mechanisms of probiotics or symbiotics are challenging with pathogenic microorganisms for intestinal epithelial receptors, which leave useful antimicrobial combinations that activates pathogenic microbes and alter and block toxins [15].…”

Section: Discussionmentioning

confidence: 99%

Effect of symbiotic supplementation on glycemic control, lipid profiles and microalbuminuria in patients with non-obese type 2 diabetes: a randomized, double-blind, clinical trial

Ebrahimi

Nasli‐Esfahani

Nadjarzade

et al. 2017

J Diabetes Metab Disord

View full text Add to dashboard Cite

BackgroundThe prevalent raise of type 2 diabetes (T2D) around the globe, are creating higher risk for cardiovascular diseases (CVDs) and increasing strain on each country’s health care budget in the world. Microalbuminuria has appeared as a key parameter in diabetic patients. Microalbuminuria is also related to increased cardiovascular morbidity in people who are non-obese diabetic. Some studies have suggested that consumption of symbiotic foods might help improve the metabolic profile, inflammatory factors and biomarkers of oxidative stress. The aim of trial was to determine the effect of symbiotic supplementation on glycemic control, lipid profiles and microalbuminuria in non-obese T2D.MethodsIn this randomized, double-blind, clinically controlled trial, 70 patients with T2D (28 females, 42 males) were randomly divided into two groups (n = 35 for each group). The symbiotic group (SG) consumed 500 mg/d of symbiotic supplementations containing probiotics (Lactobacillus family, Bifidobacterium family, Streptococus thermophilus), Prebiotics (Fructo oligosaccharide) and B group vitamins (1 mg), lactose (0.5 mg), malt-dextrin, magnesium saturate and the placebo group (PG) consumed capsules filled with row starch and also B group vitamins (1 mg), lactose (0.5 mg), malt-dextrin, magnesium saturate for 9 weeks. Fasting blood glucose (FBG), hemoglobin A1c (HbA1c), blood lipid profiles, 24-h dietary recalls, and anthropometric measurements were measured at the baseline and at the end of trial. SPSS software, version 16 was used to test the data and the results were expressed as mean ± standard deviation. Paired samples T-Test were used to compare continuous variables within groups. Comparison between different groups was performed through two independent samples T-Test. In the absence of normal distribution, the comparison between the groups was made using non-parametric Wilcoxon on signed ranks and Mann–Whitney tests. P values <0.05 was considered significant.ResultsSymbiotic supplementation decreased significantly, FBG (P = 0.05) and HbA1c (P < 0.01). There were no significant differences in lipid profiles within and between the groups at the end of study (P > 0.05). Microalbuminuria (P < 0.05) and HbA1c (P < 0.05) are increased significantly in PG at the end of the study. Furthermore, the mean changes of microalbuminuria and HbA1c experienced significant between the two groups. There was significant reduction in urea between two groups from baseline (P = 0.051). No significant changes in baseline were shown in creatinine among the two groups or within either groups (P > 0.05).ConclusionThe consumption of 500 mg/d symbiotic supplementation for 9 weeks could improve the HbA1c, BMI and Microalbuminuria in T2D. Although, No effect has been indicated on FBS, lipid profiles, urea and creatinine.Trial RegistrationThe trial has been registered in the Iranian Registry of Clinical Trials IRCT2015072223284N1, identifier. Registered 21 May 2016 “retrospectively registered”.

show abstract

“…The findings of this study revealed the efficiency of L. plantarum TN627 in preserving the liver and kidney tissues of diabetic rats, which was evidenced by the lower rates observed for hepatic and renal dysfunction indices. This strong therapeutic potential of L. plantarum TN627 is presumably attributed to its inherent hypoglycemic and hypolipidemic properties [15,18].…”

Section: Discussionmentioning

confidence: 99%

“…For example, the efficiency of using probiotics for the prevention of hypertension and cardiovascular pathologies through the reduction of serum cholesterol levels has been well documented in the literature [15À17]. The probiotic Lactobacillus reuteri GMNL-263 has also been demonstrated to induce significant protective effects on renal fibrosis caused by hyperglycemia [18].…”

Section: Introductionmentioning

confidence: 99%

Lactobacillus plantarum TN627 significantly reduces complications of alloxan-induced diabetes in rats

et al. 2013

View full text Add to dashboard Cite

Effect of Lactobacillus reuteri GMNL-263 treatment on renal fibrosis in diabetic rats

Cited by 43 publications

References 30 publications

RETRACTED ARTICLE: Obesity-associated gut microbiota is enriched in Lactobacillus reuteri and depleted in Bifidobacterium animalis and Methanobrevibacter smithii

RETRACTED ARTICLE: Obesity-associated gut microbiota is enriched in Lactobacillus reuteri and depleted in Bifidobacterium animalis and Methanobrevibacter smithii

Effect of symbiotic supplementation on glycemic control, lipid profiles and microalbuminuria in patients with non-obese type 2 diabetes: a randomized, double-blind, clinical trial

Lactobacillus plantarum TN627 significantly reduces complications of alloxan-induced diabetes in rats

Contact Info

Product

Resources

About